CatalystWireBeta

Publication of Equity Research

In brief · summary, not quotable

SP Angel Corporate Finance and Oberon Capital initiate equity research coverage on Renalytix.

Full announcement

Select text to share a quote on X · sign in to keep highlights & notes in your RENX notes

LONDON and NEW YORK, 9 November 2026 – Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company focused on kidney disease, confirms that SP Angel Corporate Finance LLP and Oberon Capital have initiated coverage on the Company.

The new equity research notes are both available on Research Tree (https://www.research-tree.com/) and have been published on the following research portals:

SP Angel Corporate Finance

Oberon Capital

RenalytixTM (LSE: RENX) (OTCQB: RNLXY) is an artificial intelligence-enabled in vitro diagnostics company dedicated to optimizing kidney disease management through precision-based care intervention. Its KidneyIntelX™ technology and data-driven insights help clinical teams understand patient level of risk for progressive decline in kidney function in the earliest stages of diabetic kidney disease. This enables clinicians to focus resources and guideline-recommended treatment, providing the best chance for improving kidney and overall renal-cardio-metabolic outcomes.

Unrecognized and uncontrolled diabetic kidney disease remains one of the largest barriers to reducing suffering and controlling cost in the United States and United Kingdom medical systems, affecting approximately 15 million and 8 million people, respectively.

Cleaned text: letterheads, contacts and legal notices removed. Regulatory announcement (RNS) as filed by the company. Not investment advice.

Share this quote

Quote card
Post on X WhatsApp Download image

The link opens this announcement with the quote highlighted. Quotes are checked against the original text.

Add a note